drugset / Trial / NCT03477903
TAK-954 in Critically Ill Participants With Enteral Feeding Intolerance (EFI)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to assess the treatment effect of intravenous TAK-954 in improving the average daily protein adequacy received through enteral nutrition in critically-ill participants developing EFI.
Timeline
- Start
- 2018-08-25
- Primary completion
- 2018-08-29
- Completion
- 2018-08-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Metoclopramide | Small molecule | 10 mg | Intravenous |
| Subject | felcisetrag | Small molecule | 0.1 mg | Intravenous |
| Subject | felcisetrag | Small molecule | 0.3 mg | Intravenous |
| Subject | felcisetrag | Small molecule | 1 mg | Intravenous |
Indications
No indication recorded.